Karyopharm CFO Michael Mason to resign Nov 5; transition agreement signed

Karyopharm Therapeutics Inc.

Michael Mason, EVP/CFO/Treasurer, notified resignation effective November 5, 2024; will serve until then.
Company initiated search for a successor CFO.
Transition agreement provides $100,000 lump sum payable on Nov 6, 2024, if employed through resignation.
Mason to enter consulting agreement through March 1, 2025, with continued vesting of equity awards.
Consulting fee: hourly pay after 5th hour each month; equity vesting continues during consultation.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Michael Mason

Executive Vice President, Chief Financial Officer and Treasurer

KPTI · Karyopharm Therapeutics Inc.

Effective: 2024-11-05
Filed: August 29, 2024, 7:59 PM ET

On August 26, 2024, Michael Mason notified Karyopharm Therapeutics Inc. (the “Company”) of his intention to resign as the Company’s Executive Vice President, Chief Financial Officer and Treasurer to pursue other professional interests.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Mason resigned as Executive Vice President, Chief Financial Officer and Treasurer at Karyopharm Therapeutics Inc..

Action: resigned
Role: Executive Vice President, Chief Financial Officer and Treasurer

Exact text from the filing

On August 26, 2024, Michael Mason notified Karyopharm Therapeutics Inc. (the “Company”) of his intention to resign as the Company’s Executive Vice President, Chief Financial Officer and Treasurer to pursue other professional interests.

View on SEC.gov

Karyopharm Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-209907

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.